These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37783655)

  • 1. HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Pinto E; Pelizzaro F; Cardin R; Battistel M; Palano G; Bertellini F; Kitenge MP; Peserico G; Farinati F; Russo FP
    Dig Liver Dis; 2024 May; 56(5):872-879. PubMed ID: 37783655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of recurrence for serum hypoxia inducible factor-1α C-reaction protein in hepatocellular carcinoma patients after transcatheter arterial chemoembolization.
    Jing Q; Jianyong L; Jiming Y; Shuren L; Rui W; Wei L
    Indian J Cancer; 2015 Dec; 52 Suppl 2():e105-6. PubMed ID: 26728665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer.
    Jia ZZ; Jiang GM; Feng YL
    Chin Med Sci J; 2011 Sep; 26(3):158-62. PubMed ID: 22207924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
    El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
    J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations between serum hypoxia inducible factor-1α, vascular endothelial growth factor and computed tomography perfusion imaging at pre-and post-TACE in patients with primary hepatic carcinoma].
    Jia ZZ; Huang YQ; Feng YL; Jiang GM
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(19):1472-5. PubMed ID: 24029570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
    Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
    Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
    Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.
    Xu W; Kwon JH; Moon YH; Kim YB; Yu YS; Lee N; Choi KY; Kim YS; Park YK; Kim BW; Wang HJ
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1507-15. PubMed ID: 24853275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
    Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
    Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.
    Ranieri G; Ammendola M; Marech I; Laterza A; Abbate I; Oakley C; Vacca A; Sacco R; Gadaleta CD
    World J Gastroenterol; 2015 May; 21(19):6018-25. PubMed ID: 26019468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
    Poon RT; Lau C; Yu WC; Fan ST; Wong J
    Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim SS; Cho HJ; Won JH; Bae JI; Kang DR; Lee JD; Shin SJ; Lee KM; Yoo BM; Kim JK; Lee JH; Ahn SJ; Park JH; Cho SW; Cheong JY
    Cytokine; 2015 Dec; 76(2):449-457. PubMed ID: 26163999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
    Shim JH; Park JW; Kim JH; An M; Kong SY; Nam BH; Choi JI; Kim HB; Lee WJ; Kim CM
    Cancer Sci; 2008 Oct; 99(10):2037-44. PubMed ID: 19016764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
    Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
    BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
    Qu K; Yan Z; Wu Y; Chen Y; Qu P; Xu X; Yuan P; Huang X; Xing J; Zhang H; Liu C; Zhang J
    J Gastroenterol Hepatol; 2015 May; 30(5):925-32. PubMed ID: 25641377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.